CAM
IBB icon

Cresset Asset Management’s iShares Biotechnology ETF IBB Stock Holding History

Cresset Asset Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.22M Sell
11,649
-532
-4% -$91.4K 0.01% 638
2026
Q1 		$2.06M Buy
12,181
+2,811
+30% +$481K 0.01% 556
2025
Q4 		$1.58M Buy
9,370
+483
+5% +$78.4K 0.01% 635
2025
Q3 		$1.28M Buy
8,887
+102
+1% +$13.9K 0.01% 663
2025
Q2 		$1.11M Sell
8,785
-1,842
-17% -$226K 0.01% 655
2025
Q1 		$1.36M Sell
10,627
-734
-6% -$99.5K 0.01% 662
2024
Q4 		$1.5M Sell
11,361
-5,994
-35% -$843K 0.01% 639
2024
Q3 		$2.53M Sell
17,355
-1,851
-10% -$268K 0.01% 687
2024
Q2 		$2.64M Buy
19,206
+3,426
+22% +$457K 0.01% 611
2024
Q1 		$2.17M Buy
15,780
+169
+1% +$23.1K 0.01% 611
2023
Q4 		$2.12M Sell
15,611
-953
-6% -$116K 0.01% 562
2023
Q3 		$2.03M Sell
16,564
-1,010
-6% -$128K 0.01% 553
2023
Q2 		$2.23M Buy
17,574
+7,711
+78% +$1M ﹤0.01% 616
2023
Q1 		$1.27M Buy
9,863
+3,136
+47% +$411K 0.03% 297
2022
Q4 		$574K Sell
6,727
-419
-6% -$54.1K 0.01% 402
2022
Q3 		$837K Buy
7,146
+407
+6% +$50.5K 0.01% 391
2022
Q2 		$793K Buy
6,739
+3,547
+111% +$421K 0.01% 427
2022
Q1 		$416K Sell
3,192
-965
-23% -$126K ﹤0.01% 663
2021
Q4 		$634K Buy
4,157
+2,698
+185% +$418K 0.01% 616
2021
Q3 		$236K Buy
1,459
+150
+11% +$25.2K ﹤0.01% 955
2021
Q2 		$214K Sell
1,309
-1,149
-47% -$177K ﹤0.01% 924
2021
Q1 		$370K Buy
2,458
+235
+11% +$37.3K 0.01% 581
2020
Q4 		$337K Buy
2,223
+455
+26% +$65K 0.01% 521
2020
Q3 		$240K Buy
+1,768
New +$240K ﹤0.01% 582
2019
Q2 		– Sell
-226
Closed -$25K – 1014
2019
Q1 		$25K Buy
226
+76
+51% +$8.34K ﹤0.01% 957
2018
Q4 		$14K Buy
+150
New +$15.9K ﹤0.01% 785

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Cresset Asset Management's IBB Position: Q2 2026 in Review

Cresset Asset Management reduced its iShares Biotechnology ETF (IBB) stake by 4.4% in Q2 2026, selling an estimated $91.4K and leaving 11,649 shares worth $2.22M. The position accounts for 0.01% of the portfolio, ranked #638.

Cresset Asset Management first reported a position in IBB in Q4 2018 and has held it in 26 quarters since. The position peaked at $2.64M in Q2 2024. 954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Cresset Asset Management held 11,649 shares of iShares Biotechnology ETF worth $2.22M as of Q2 2026.
  • Cresset Asset Management sold 532 iShares Biotechnology ETF shares in Q2 2026, an estimated $91.4K.
  • iShares Biotechnology ETF made up 0.01% of Cresset Asset Management's portfolio in Q2 2026, its #638 holding.
  • Cresset Asset Management first reported a position in iShares Biotechnology ETF in Q4 2018 and has held it in 26 quarters since.
  • Cresset Asset Management's iShares Biotechnology ETF position peaked at $2.64M in Q2 2024.
  • 954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.